-
Complications and management of hyperkalemia: implications for the use of the novel cation exchangers zirconium cyclosilicate and patiromer
Lama Noureddine & Bradley S Dixon
Review: Clinical Trail Outcomes: Clinical Investigation
-
Complications and management of hyperkalemia: implications for the use of the novel cation exchangers zirconium cyclosilicate and patiromer
Lama Noureddine & Bradley S Dixon
Review: Clinical Trail Outcomes: Clinical Investigation
-
Complications and management of hyperkalemia: implications for the use of the novel cation exchangers zirconium cyclosilicate and patiromer
Lama Noureddine & Bradley S Dixon
Review: Clinical Trail Outcomes: Clinical Investigation
-
Complications and management of hyperkalemia: implications for the use of the novel cation exchangers zirconium cyclosilicate and patiromer
Lama Noureddine & Bradley S Dixon
Review: Clinical Trail Outcomes: Clinical Investigation
-
Complications and management of hyperkalemia: implications for the use of the novel cation exchangers zirconium cyclosilicate and patiromer
Lama Noureddine & Bradley S Dixon
Review: Clinical Trail Outcomes: Clinical Investigation
-
Complications and management of hyperkalemia: implications for the use of the novel cation exchangers zirconium cyclosilicate and patiromer
Lama Noureddine & Bradley S Dixon
Review: Clinical Trail Outcomes: Clinical Investigation
-
Complications and management of hyperkalemia: implications for the use of the novel cation exchangers zirconium cyclosilicate and patiromer
Lama Noureddine & Bradley S Dixon
Review: Clinical Trail Outcomes: Clinical Investigation
-
Complications and management of hyperkalemia: implications for the use of the novel cation exchangers zirconium cyclosilicate and patiromer
Lama Noureddine & Bradley S Dixon
Review: Clinical Trail Outcomes: Clinical Investigation
-
Updating the clinical evidence on belimumab role modulating B-cell response and treatment of systemic lupus erythematosus
Ignasi Rodriguez-Pinto, Gerard Espinosa1 & Ricard Cervera
Drug Evaluation: Clinical Investigation
-
Updating the clinical evidence on belimumab role modulating B-cell response and treatment of systemic lupus erythematosus
Ignasi Rodriguez-Pinto, Gerard Espinosa1 & Ricard Cervera
Drug Evaluation: Clinical Investigation
-
Updating the clinical evidence on belimumab role modulating B-cell response and treatment of systemic lupus erythematosus
Ignasi Rodriguez-Pinto, Gerard Espinosa1 & Ricard Cervera
Drug Evaluation: Clinical Investigation
-
Updating the clinical evidence on belimumab role modulating B-cell response and treatment of systemic lupus erythematosus
Ignasi Rodriguez-Pinto, Gerard Espinosa1 & Ricard Cervera
Drug Evaluation: Clinical Investigation
-
Updating the clinical evidence on belimumab role modulating B-cell response and treatment of systemic lupus erythematosus
Ignasi Rodriguez-Pinto, Gerard Espinosa1 & Ricard Cervera
Drug Evaluation: Clinical Investigation
-
Updating the clinical evidence on belimumab role modulating B-cell response and treatment of systemic lupus erythematosus
Ignasi Rodriguez-Pinto, Gerard Espinosa1 & Ricard Cervera
Drug Evaluation: Clinical Investigation
-
Updating the clinical evidence on belimumab role modulating B-cell response and treatment of systemic lupus erythematosus
Ignasi Rodriguez-Pinto, Gerard Espinosa1 & Ricard Cervera
Drug Evaluation: Clinical Investigation
-
Updating the clinical evidence on belimumab role modulating B-cell response and treatment of systemic lupus erythematosus
Ignasi Rodriguez-Pinto, Gerard Espinosa1 & Ricard Cervera
Drug Evaluation: Clinical Investigation
-
Ibudilast for the treatment of drug addiction and other neurological conditions
Kirk W Johnson, Kazuko Matsuda & Yuichi Iwaki
Review: Clinical Trail Outcomes: Clinical Investigation
-
Ibudilast for the treatment of drug addiction and other neurological conditions
Kirk W Johnson, Kazuko Matsuda & Yuichi Iwaki
Review: Clinical Trail Outcomes: Clinical Investigation
-
Ibudilast for the treatment of drug addiction and other neurological conditions
Kirk W Johnson, Kazuko Matsuda & Yuichi Iwaki
Review: Clinical Trail Outcomes: Clinical Investigation
-
Ibudilast for the treatment of drug addiction and other neurological conditions
Kirk W Johnson, Kazuko Matsuda & Yuichi Iwaki
Review: Clinical Trail Outcomes: Clinical Investigation
-
Ibudilast for the treatment of drug addiction and other neurological conditions
Kirk W Johnson, Kazuko Matsuda & Yuichi Iwaki
Review: Clinical Trail Outcomes: Clinical Investigation
-
Ibudilast for the treatment of drug addiction and other neurological conditions
Kirk W Johnson, Kazuko Matsuda & Yuichi Iwaki
Review: Clinical Trail Outcomes: Clinical Investigation
-
Ibudilast for the treatment of drug addiction and other neurological conditions
Kirk W Johnson, Kazuko Matsuda & Yuichi Iwaki
Review: Clinical Trail Outcomes: Clinical Investigation
-
Ibudilast for the treatment of drug addiction and other neurological conditions
Kirk W Johnson, Kazuko Matsuda & Yuichi Iwaki
Review: Clinical Trail Outcomes: Clinical Investigation
-
Antiprotozoals for human African trypanosomiasis: the heart of darkness at dawn
Christian Burri
Commentary: Clinical Investigation
-
Antiprotozoals for human African trypanosomiasis: the heart of darkness at dawn
Christian Burri
Commentary: Clinical Investigation
-
Antiprotozoals for human African trypanosomiasis: the heart of darkness at dawn
Christian Burri
Commentary: Clinical Investigation
-
Antiprotozoals for human African trypanosomiasis: the heart of darkness at dawn
Christian Burri
Commentary: Clinical Investigation
-
Antiprotozoals for human African trypanosomiasis: the heart of darkness at dawn
Christian Burri
Commentary: Clinical Investigation
-
Antiprotozoals for human African trypanosomiasis: the heart of darkness at dawn
Christian Burri
Commentary: Clinical Investigation
-
Antiprotozoals for human African trypanosomiasis: the heart of darkness at dawn
Christian Burri
Commentary: Clinical Investigation
-
Antiprotozoals for human African trypanosomiasis: the heart of darkness at dawn
Christian Burri
Commentary: Clinical Investigation
-
Polypill (fixed-dose combinations) in the prevention of cardiovascular disease: rationale and clinical data
Kavita Singh, Abdul Salam, Raji Devarajan, Anushka Patel4, Dorairaj Prabhakaran
Review: Clinical Trail Outcomes: Clinical Investigation
-
Polypill (fixed-dose combinations) in the prevention of cardiovascular disease: rationale and clinical data
Kavita Singh, Abdul Salam, Raji Devarajan, Anushka Patel4, Dorairaj Prabhakaran
Review: Clinical Trail Outcomes: Clinical Investigation
-
Polypill (fixed-dose combinations) in the prevention of cardiovascular disease: rationale and clinical data
Kavita Singh, Abdul Salam, Raji Devarajan, Anushka Patel4, Dorairaj Prabhakaran
Review: Clinical Trail Outcomes: Clinical Investigation
-
Polypill (fixed-dose combinations) in the prevention of cardiovascular disease: rationale and clinical data
Kavita Singh, Abdul Salam, Raji Devarajan, Anushka Patel4, Dorairaj Prabhakaran
Review: Clinical Trail Outcomes: Clinical Investigation
-
Polypill (fixed-dose combinations) in the prevention of cardiovascular disease: rationale and clinical data
Kavita Singh, Abdul Salam, Raji Devarajan, Anushka Patel4, Dorairaj Prabhakaran
Review: Clinical Trail Outcomes: Clinical Investigation
-
Polypill (fixed-dose combinations) in the prevention of cardiovascular disease: rationale and clinical data
Kavita Singh, Abdul Salam, Raji Devarajan, Anushka Patel4, Dorairaj Prabhakaran
Review: Clinical Trail Outcomes: Clinical Investigation
-
Polypill (fixed-dose combinations) in the prevention of cardiovascular disease: rationale and clinical data
Kavita Singh, Abdul Salam, Raji Devarajan, Anushka Patel4, Dorairaj Prabhakaran
Review: Clinical Trail Outcomes: Clinical Investigation
-
Polypill (fixed-dose combinations) in the prevention of cardiovascular disease: rationale and clinical data
Kavita Singh, Abdul Salam, Raji Devarajan, Anushka Patel4, Dorairaj Prabhakaran
Review: Clinical Trail Outcomes: Clinical Investigation
-
Pediatric drug development: unmet medical needs and opportunities for collaboration between industry, academia and the US FDA
Lisa Mathis,Hong Vu, Andrew E Mulberg
: Clinical Investigation
-
Pediatric drug development: unmet medical needs and opportunities for collaboration between industry, academia and the US FDA
Lisa Mathis,Hong Vu, Andrew E Mulberg
: Clinical Investigation
-
Pediatric drug development: unmet medical needs and opportunities for collaboration between industry, academia and the US FDA
Lisa Mathis,Hong Vu, Andrew E Mulberg
: Clinical Investigation
-
Pediatric drug development: unmet medical needs and opportunities for collaboration between industry, academia and the US FDA
Lisa Mathis,Hong Vu, Andrew E Mulberg
: Clinical Investigation
-
Pediatric drug development: unmet medical needs and opportunities for collaboration between industry, academia and the US FDA
Lisa Mathis,Hong Vu, Andrew E Mulberg
: Clinical Investigation
-
Pediatric drug development: unmet medical needs and opportunities for collaboration between industry, academia and the US FDA
Lisa Mathis,Hong Vu, Andrew E Mulberg
: Clinical Investigation
-
Pediatric drug development: unmet medical needs and opportunities for collaboration between industry, academia and the US FDA
Lisa Mathis,Hong Vu, Andrew E Mulberg
: Clinical Investigation
-
Pediatric drug development: unmet medical needs and opportunities for collaboration between industry, academia and the US FDA
Lisa Mathis,Hong Vu, Andrew E Mulberg
: Clinical Investigation